Nova Eye Medical FY21 H1 Investor Presentation

Nova Eye Medical presents its first-half FY21 financial and operational results, focusing on its dual-segment business of glaucoma surgical devices and laser therapy for retinal conditions. The company highlights progress in minimally invasive glaucoma surgery through proprietary technologies iTrack and Molteno3, targeting a US$4.9 billion glaucoma market with 82 million patients globally.